Arthrosi Therapeutics, Inc. was founded in San Diego, CA, in 2018, by a world-class team of gout experts who spearheaded the clinical development of the first generation of urate inhibitor treatment for gout at Ardea Biosciences resulting in a $1.26 Billion acquisition by AstraZeneca. With its vast therapeutic and treatment knowledge, Arthrosi has efficiently completed multiple robust phase 1 and 2 clinical studies in a mere two years and accumulated a comprehensive and robust intellectual property portfolio.
Our proprietary molecule, AR882, is designed to lower uric acid, diminish tophi, and reduce gout flares – without renal safety issues. The new molecule has shown unmatched promise, with industry-leading efficacy rates
and superior safety profiles in Phase 1 and 2 trials.
- Best-in-class urate lowering agent among in-development and marketed drugs
- Demonstrated efficacy for potential flare and tophi reduction, even among patients with renal impairment
- Demonstrated excellent safety profile in patients with various degrees of renal impairment
- Potential to treat all stages of gout .
Our Mission & Vision
When it comes to living with gout, reducing debilitating flares, and preventing irreversible joint damage is the goal. Yet a large percentage of the more than 9 million patients living with gout are undertreated, relying on short-term or sub-optimal treatments that do not provide a true solution for strong uric acid reduction and the resolution of joint damage caused by tophi.
At Arthrosi, we aspire to bring:
First blockbuster gout therapeutic
A true solution for reducing flare and tophi
Speed and efficiency to market to bring the benefits to patients.
High rewards to our partners and investors